Ward K W, Nagilla R, Jolivette L J
Preclinical Drug Discovery, Cardiovascular & Urogenital Centre of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA 19406, USA.
Xenobiotica. 2005 Feb;35(2):191-210. doi: 10.1080/00498250400028197.
The prediction of human pharmacokinetics is often based on in vivo preclinical pharmacokinetic data. However, to date, no clear guidance has been available about the relative ability of the major preclinical species to estimate human oral exposure. The study was conducted to survey the literature on oral pharmacokinetic parameters in rat, dog, monkey and human, and to compare various methods for prediction of oral exposure in humans. Fifty-six non-peptide xenobiotics were identified with oral pharmacokinetic data in rat, dog, monkey and human, and comparison of the data from each species to humans was conducted along with an evaluation of the molecular features of these compounds. Monkey liver blood flow-based oral exposure was qualitatively and quantitatively more predictive of human oral exposure than rat or dog. Furthermore, generation of data in three versus two preclinical species did not always improve human predictivity. The use of molecular properties did not substantially improve the prediction of human oral exposure compared with the prediction from monkey alone. These observations confirm the continued importance of non-human primates in preclinical pharmacokinetics, and also have implications for pharmacokinetic lead optimization and for prediction of human pharmacokinetic parameters from in vivo preclinical data.
人类药代动力学的预测通常基于临床前体内药代动力学数据。然而,迄今为止,关于主要临床前物种估算人类口服暴露量的相对能力,尚无明确的指导意见。开展这项研究旨在调查大鼠、犬、猴和人类口服药代动力学参数的相关文献,并比较预测人类口服暴露量的各种方法。确定了56种非肽类异生物素在大鼠、犬、猴和人类中的口服药代动力学数据,并将每个物种的数据与人类数据进行比较,同时对这些化合物的分子特征进行评估。与大鼠或犬相比,基于猴肝血流量的口服暴露量在定性和定量方面对人类口服暴露量的预测性更强。此外,使用三种临床前物种而非两种所生成的数据,并不总能提高对人类的预测性。与仅根据猴进行的预测相比,利用分子特性并未显著改善对人类口服暴露量的预测。这些观察结果证实了非人类灵长类动物在临床前药代动力学中的持续重要性,也对药代动力学先导化合物优化以及从临床前体内数据预测人类药代动力学参数具有启示意义。